Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

National Immunization Strategy 2017-2022


Foreword
 
There have been many transformations to the NIP inthe recent years. New vaccines wereadded to the vaccination schedule, the cohorts served by the public sector kepton expandingsince the onset of the Syrian crisis, measures to consolidatethe vaccine purchasing arrangements were adopted,and there wasa leveraging up ofthe vaccinovigilanceand its effective management.In 2016, the Ministryof health in Lebanon decided that it was the time to take stock, constructon the current NIP strengthsand achievements andidentify areas for further improvement. A strategy for the NIP for 2016-2020 wasenvisagedin agreementwith the development partners. A detailed situation analysis assessment was initiatedin October 2015 in two stages: at the initial stage, the country and health system contexts were analyzed, and immunization system performance was measured. In the second stage, a framework was developed in consultations with key stakeholders to define gaps in the evidence. Immunization coverage evaluation survey was conducted in 2016 and fed into filling the lacunas in information.

The present document expresses the country vision, goals and priorities of the national immunization program. It relies on a careful examination of the situation analysis, an assessment of the enablers and challenges facing the immunization services and defines the national immunization strategies addressing these contests. The strategies were formulated as informed choices across more than one solution deemed most feasible and efficient considering the country context.

The document is structured in three sections:

Section 1“Situational analysis” presents briefly the organization and operation of the national immunization program as well as the recent achievements and remaining challenges,

Section 2 “Conceptual framework” describes the future vision of the country in regards to vaccine preventable diseases, the long term goals to be achieved and the more specific results –immunization system objectives and targets for 2020,

Section 3 defines the Strategies to address the bottlenecks and achieve immunization system objectives by 2020. Most of strategies (so called “immunization system specific” ones) are presented by relevant health system blocks.The focus of the NIP Strategy, is to assistthe MOPH to meet international goals set by the World Health Organization (WHO) under the Global Immunization Vision and Strategy (GIVS). The Strategy articulates action areas to conserve the successful achievements of the last years, built on the current favoring momentum and propose solutions for the drawbacks

The Strategy comprises nineStrategic Priority Areas to complement and strengthen the NIP.

The matrix (Figure 2) in Annexesshows expected results of the immunization system development strategies by health system building blocks and links them to the root causes (weaknesses and treats) identified during the system analysis...
    ...
    160
    ...
ATC Name B/G Ingredients Dosage Form Price
G04BD06 MICTONORM B Propiverine HCl - 5mg 5mg Tablet, coated 1,917,663 L.L
C09AA03 TENSIKEY G Lisinopril - 5mg 5mg Tablet 456,906 L.L
N04AA01 BENZHEXOL G Trihexyphenidyl - 5mg 5mg Tablet, scored 533,697 L.L
G04BD08 VESICARE B Solifenacin succinate - 5mg 5mg Tablet, film coated 1,619,330 L.L
G04BD08 ASOLFENA G Solifenacin succinate - 5mg 5mg Tablet, film coated 971,598 L.L
G04BD08 SOLIFENACINE ARROW G Solifenacin succinate - 5mg 5mg Tablet 952,784 L.L
C09AA04 COVERSYL ARGININE B Perindopril arginine - 5mg 5mg Tablet, film coated 452,875 L.L
G04BD08 SOLIFAS G Solifenacin succinate - 5mg 5mg Tablet, film coated 971,598 L.L
G04BD08 URISOL G Solifenacin succinate - 5mg 5mg Tablet, film coated 1,334,884 L.L
G04BD08 URICARE G Solifenacin succinate - 5mg 5mg Tablet, film coated 1,334,884 L.L
A03FA09 MOSAR B Mosapride citrate - 5mg 5mg Tablet, coated 798,242 L.L
N06AB10 PRAMACYT 5 G Escitalopram (oxalate) - 5mg 5mg Tablet, film coated 895,895 L.L
N06AB10 PRYLEX 5 G Escitalopram (oxalate) - 5mg 5mg Tablet, film coated 895,895 L.L
C09AA05 TRITACE B Ramipril - 5mg 5mg Tablet 509,316 L.L
N06AB10 CITOXAL G Escitalopram (oxalate) - 5mg 5mg Tablet, film coated 895,895 L.L
C09AA05 APO-RAMIPRIL G Ramipril - 5mg 5mg Capsule 794,211 L.L
C09AA05 ACURIL G Ramipril - 5mg 5mg Tablet 614,136 L.L
C09AA05 RAMIPRIL-REMEDICA G Ramipril - 5mg 5mg Tablet 623,543 L.L
C09AA05 NORMOPRIL G Ramipril - 5mg 5mg Tablet 474,376 L.L
C09AA05 TRILTEC G Ramipril - 5mg 5mg Capsule 447,948 L.L
L01EG02 AFINITOR B Everolimus - 5mg 5mg Tablet 131,002,184 L.L
L04AD02 PROGRAF 5MG B Tacrolimus - 5mg 5mg Capsule L.L
L01EG02 EVEROLIMUS BIOGARAN G Everolimus - 5mg 5mg Tablet 89,386,347 L.L
L01EG02 EVEROLIMUS ARROW G Everolimus - 5mg 5mg Tablet 66,619,921 L.L
C01EB17 PROCORALAN B Ivabradin (HCl) - 5mg 5mg Tablet, film coated 1,890,786 L.L
C01EB17 IVABRADINE ARROW G Ivabradine (HCl) - 5mg 5mg Tablet, film coated, scored 1,323,685 L.L
C01EB17 BRAVIGO G Ivabradine (HCl) - 5mg 5mg Tablet, film coated 1,237,679 L.L
N05AB02 FLUPHENAZINE HCl G Fluphenazine (HCl) - 5mg 5mg Tablet, scored 624,567 L.L
L01EJ01 JAKAVI B Ruxolitinib - 5mg 5mg Tablet 151,681,526 L.L
L01EJ01 CELEZON G Ruxolitinib - 5mg 5mg Tablet 95,532,998 L.L
    ...
    160
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2025